Eli Lilly raises full-year forecast, sees sustained demand for weight-loss drugs

Core Insights - Eli Lilly has raised its full-year profit and revenue forecast, driven by increasing demand for its GLP-1 drugs [1] Company Summary - The company is experiencing a surge in demand for its blockbuster GLP-1 drugs, which has led to an optimistic outlook for the year [1] Industry Summary - The performance of Eli Lilly reflects a broader trend in the pharmaceutical industry, particularly in the market for GLP-1 medications, which are gaining popularity [1]